FT : France scores diplomatic wins on banks and nuclear in new EU rules

France scores diplomatic wins on banks and nuclear in new EU rules
Paris successfully pushed for weaker due diligence reporting by lenders and state-backed funding for nuclear power plants

France has secured a partial carve-out for banks from new EU rules to make companies responsible for environmental impacts in their supply chains.

Paris also won, in separate negotiations, assurance that state-backed funding for its nuclear power plants will be possible under a reform of the EU electricity market, the culmination of a concerted effort to champion the low-carbon fuel in the face of opposition from Luxembourg, Austria and Germany.

Agnès Pannier-Runacher, French energy minister, hailed the decision as “excellent news”. “It gives us the means to ensure long-term financing for the transformation of our electricity system,” she said.

The EU due diligence law agreed on Thursday will force companies with more than 500 employees and €150mn in revenue to report and take measures to prevent worker exploitation, deforestation and pollution in their supply chains. Civil society groups will have the ability to take businesses to court for non-compliance with the rules.

France, backed by countries including Italy and the Czech Republic, has succeeded in making sure that banks, asset managers and investment groups will only have to report on upstream activities such as purchasing office equipment.

They will not have to undertake due diligence on the activities of clients to whom they are offering loans — something that the European parliament had pushed for in the talks.

In a note circulated among negotiators earlier this month, the European Central Bank also warned that “excluding the financial sector would be counterproductive to the intention of the [law], as it would allow the EU financial sector to continue to fund activities detrimental to the EU [environmental and social governance] agenda”.

Arianne Griffith, corporate accountability lead at the NGO Global Witness, said that it was “shocking” that EU countries had “sunk plans to ensure that banks stop investing in environmental and human rights abuses”.

Eelco Van der Enden, chief executive of the Global Reporting Initiative, said that it was “disheartening” to see that the French effort had watered down the application of the rules to the financial sector but that a review clause in the agreement could offer the opportunity to include them at a later stage.

Banks with more than 500 employees will, however, have to draw up and implement climate transition plans to show what they are doing to mitigate their impact on global warming.

Richard Gardiner, head of EU policy at the World Benchmarking Alliance, said that “the significant upside” of the law was the obligation for banks to adopt and implement a “meaningful transition plan”, overriding current voluntary pledges to bring carbon emissions to zero.

Both the energy market reform and the due diligence rules must be formally approved by the European parliament and member states in votes due to take place early next year. Once the due diligence directive is approved, EU governments will have two years to introduce the rules in national legislation.

FT : Vivendi: break-up would reward Bolloré family with rule of three

Vivendi: break-up would reward Bolloré family with rule of three
The media conglomerate remains influential in the francophone world

If Vivendi today were the Rolling Stones then Mick Jagger would have already left the band. Universal Music was the frontman of the French media conglomerate that is controlled by French tycoon Vincent Bolloré.

The record label — home to Their Satanic Majesties among others — was successfully spun off in 2021 for €47bn. The rest of the group took it hard. Fans have abandoned Vivendi’s shares and the conglomerate discount is now close to 40 per cent. The Bolloré family was spurred to act. A fuller break-up of the business should follow. 

The proposal would mean new solo stock market careers for broadcaster Canal+ and advertising agency Havas. The remaining Bolloré interests, such as stakes in publisher Lagardère and Telecom Italia, would continue within a listed holding company.

A simple sum of the parts suggests the break-up of the group, worth €11.2bn before news broke, would be an easy financial win. Longer-term strategic goals should be simpler for solo acts to achieve.

Vivendi remains influential in the francophone world. That linkage has helped Canal+ to resist US streaming services like Netflix in recent years. The broadcaster has managed to integrate streaming services into its own offering. Profits have grown solidly since 2016.

If we value Canal+ at six times ebitda like UK broadcaster ITV, it would have an enterprise value of €5bn. Supposing Havas is worth a multiple of seven times like peers Publicis and Interpublic, it would be worth almost €3bn.

The final gain for shareholders depends on the discount that would apply to the investment holding company. If it stays at 40 per cent then a further 5 per cent bump for the sum of the parts might follow a break-up. A 30 per cent discount might be fairer, says Barclays, and closer to comparable peers. It would give credit for the success of Universal. Additional returns would then move above one-tenth for the split.

Operationally, the break-up would pose some puzzles. Dividing up Vivendi’s €1.9bn cash pile would be one issue.

The break-up would deliver value. Investors could meanwhile expect the Bolloré family, these days fronted by Vivendi chair Yannick Bolloré, to continue calling the tune.

>>> US Research Calls

Research Calls I
  • Upgrades:
    • Alector (ALEC) upgraded to Buy from Hold at Stifel; tgt raised to $15
    • Antero Resources (AR) upgraded to Overweight from Equal Weight at Wells Fargo; tgt lowered to $26
    • Bank of America (BAC) upgraded to Buy from Hold at Odeon
    • Beacon Roofing Supply (BECN) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $103
    • Choice Hotels (CHH) upgraded to Neutral from Underweight at JP Morgan; tgt $115
    • Cognizant Tech (CTSH) upgraded to Equal Weight from Underweight at Barclays; tgt raised to $75
    • Coterra Energy (CTRA) upgraded to Overweight from Equal Weight at Wells Fargo; tgt lowered to $30
    • Foot Locker (FL) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $33
    • Grupo Aeroportuario Del Sureste (ASR) upgraded to Buy from Underperform at BofA Securities
    • Host Hotels (HST) upgraded to Neutral from Underweight at JP Morgan; tgt $15
    • Installed Building Products (IBP) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $199
    • Invesco (IVZ) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $20
    • Live Nation (LYV) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $110
    • Marathon Petroleum (MPC) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $169
    • Park Hotels & Resorts (PK) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $16
    • Paychex (PAYX) upgraded to Equal Weight from Underweight at Barclays; tgt raised to $126
    • PNC (PNC) upgraded to Buy from Hold at Odeon
    • Ryman Hospitality (RHP) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $102
    • Six Flags (SIX) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $32
    • Sunstone Hotel (SHO) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $10
    • Trex (TREX) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $79
    • TripAdvisor (TRIP) upgraded to Buy from Neutral at BTIG Research; tgt $25
    • Truist (TFC) upgraded to Buy from Hold at Odeon
    • TopBuild (BLD) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $387
    • U.S. Bancorp (USB) upgraded to Buy from Hold at Odeon
    • Wells Fargo (WFC) upgraded to Buy from Hold at Odeon
  • Downgrades:
    • ACADIA Pharmaceuticals (ACAD) downgraded to Hold from Buy at Deutsche Bank; tgt $25
    • Cepton (CPTN) downgraded to Hold from Buy at Craig Hallum; tgt $2.50
    • Chesapeake Energy (CHK) downgraded to Neutral from Buy at UBS; tgt lowered to $86
    • Deckers Outdoor (DECK) downgraded to Hold from Buy at Stifel; tgt raised to $709
    • Equitrans Midstream (ETRN) downgraded to Underweight from Equal Weight at Wells Fargo; tgt raised to $10
    • Excelerate Energy (EE) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $18
    • EOG Resources (EOG) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $130
    • Fulton Fincl (FULT) downgraded to Equal-Weight from Overweight at Stephens; tgt raised to $16
    • FMC Corp (FMC) downgraded to Market Perform from Outperform at BMO Capital Markets; tgt lowered to $63
    • Gaming and Leisure Properties (GLPI) downgraded to Neutral from Overweight at JP Morgan; tgt $48
    • Green Dot (GDOT) downgraded to Underweight from Equal Weight at Barclays; tgt lowered to $7
    • Northrop Grumman (NOC) downgraded to Underperform from Peer Perform at Wolfe Research; tgt $450
    • Range Resources (RRC) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $32
    • Riskified (RSKD) downgraded to Equal Weight from Overweight at Barclays; tgt $5
    • SeaWorld Entertainment (SEAS) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt lowered to $57
    • Stanley Black & Decker (SWK) downgraded to Underweight from Neutral at JP Morgan; tgt $89
  • Others:
    • 10x Genomics (TXG) initiated with a Buy at Guggenheim; tgt $60
    • American Fincl (AFG) initiated with a Buy at Janney; tgt $135
    • Arista Networks (ANET) added to US Focus List at Citigroup
    • Akoya Biosciences (AKYA) initiated with a Neutral at Guggenheim
    • American Tower (AMT) initiated with a Buy at HSBC Securities; tgt $245
    • Arch Capital (ACGL) initiated with an In-line at Evercore ISI; tgt $88
    • Cardinal Health (CAH) initiated with an Underweight at Wells Fargo; tgt $96
    • Castle Biosciences (CSTL) initiated with a Buy at Guggenheim; tgt $25
    • Cencora (COR) initiated with an Equal Weight at Wells Fargo; tgt $213
    • Cincinnati Fincl (CINF) initiated with a Neutral at Janney
    • CRH Plc. (CRH) initiated with a Buy at Truist; tgt $81
    • Crown Castle (CCI) initiated with a Hold at HSBC Securities; tgt $110
    • Cytek Biosciences (CTKB) initiated with an Overweight at Stephens; tgt $9
    • Dell (DELL) Citigroup opens 90-day Positive Catalyst Watch
    • Everest Group (EG) initiated with an In-line at Evercore ISI; tgt $431
    • Exact Sciences (EXAS) initiated with a Buy at Guggenheim; tgt $90
    • Globant (GLOB) initiated with a Buy at William O'Neil
    • Guardant Health (GH) initiated with a Neutral at Guggenheim
    • HP Inc. (HPQ) Citigroup opens 90-day Positive Catalyst Watch
    • Illumina (ILMN) initiated with a Buy at Guggenheim; tgt $155
    • Illumina (ILMN) initiated with an Overweight at Stephens; tgt $170
    • Ironwood Pharma (IRWD) initiated with an Overweight at Wells Fargo; tgt $20
    • MAC Limited (MTAL) initiated with an Outperform at National Bank Financial; tgt $14
    • Mitek Systems (MITK) initiated with a Buy at Craig Hallum; tgt $17
    • McKesson (MCK) initiated with an Equal Weight at Wells Fargo; tgt $502
    • Myriad Genetics (MYGN) initiated with a Buy at Guggenheim; tgt $23
    • Natera (NTRA) initiated with a Buy at Guggenheim; tgt $70
    • Norfolk Southern (NSC) removed from Tactical Underperform List at Evercore ISI
    • Opera (OPRA) resumed with a Buy at B. Riley Securities; tgt $20
    • Pacific Biosciences (PACB) initiated with a Neutral at Guggenheim
    • Pacific Biosciences (PACB) initiated with an Overweight at Stephens; tgt $11
    • Pagaya (PGY) initiated with a Buy at Jefferies; tgt $2.50
    • PagerDuty (PD) initiated with a Buy at BofA Securities; tgt $30
    • PSQ Holdings (PSQH) initiated with a Buy at ROTH MKM; tgt $8.50
    • Radius Recycling (RDUS) initiated with a Neutral at Seaport Research Partners
    • RenaissanceRe (RNR) initiated with an Underperform at Evercore ISI; tgt $200
    • RPM Inc (RPM) Deutsche Bank opens Catalyst Call Buy
    • Shift4 Payments (FOUR) initiated with a Buy at Seaport Research Partners; tgt $85
    • Talen Energy Corporation (TLNE) initiated with an Outperform at Oppenheimer; tgt $77
    • WK Kellogg Co (KLG) initiated with an Equal-Weight at Morgan Stanley; tgt $13
    • Zai Lab (ZLAB) initiated with an Overweight at Morgan Stanley; tgt $47.50

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • ADBE -3.6%, NUE -2.5% (guidance), MWA -0.8%
Other news:
  • OCUL -17% (prices offering of 30.8 mln shares of common stock at $3.25 per share)
  • APLS -14.1% (Provides update on ongoing regulatory review of pegcetacoplan for GA in the European Union)
  • MDRX -10% (announces that Nasdaq Hearings Panel has granted its continued listing pending return to compliance with Nasdaq filing requirements)
  • ASLE -9.4% (prices secondary offering of 4.0 mln shares of common stock by selling shareholders)
  • PBA -2.9% (purchasing stakes in two of ENB's pipelines for $3.1 bln)
  • ACAD -2.2% (Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID (pimavanserin); also downgraded to Hold from Buy at Deutsche Bank)
  • ARR -1.3% (reduces monthly dividend to $0.24 per share for January down from $0.40 pre share prior)
Analyst comments:
  • GDOT -2.8% (downgraded to Underweight from Equal Weight at Barclays)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • ALK +1.2% (guidance), NDSN +1.1%
Other news:
  • CDXS +13.9% (enters into agreement with Aldevron)
  • CARM +12.7% (announces nomination of first lead candidate under its collaboration with Moderna (MRNA))
  • ESPR +11.9% (FDA updates LDL-C for NEXLETOL and NEXLIZET)
  • MRNA +11.7% (Moderna and Merck (MRK) announce mRNA-4157 in combination with Keytruda demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage III/IV melanoma following complete resection versus Keytruda at three years)
  • GKOS +6.8% (FDA approved its New Drug Application for a single administration per eye of iDose TR 75 mcg; reaffirms FY23 revenue guidance and sees FY24 revs above consensus)
  • SDRL +5.2% (initiates new share buy-back program)
  • HOOD +3.3% (reports November data)
  • BCYC +3.2% (provides data updates for three clinical programs and strategy overview at First R&D Day)
  • ISPR +3% (subsidiary enters five-year exclusive global manufacturing and distribution agreement with lifestyle brand: BrkFst)
  • RKLB +2.4% (preparing launch of its Electron missino)
  • TXG +2.4% (releases data from new study)
  • CVE +2.4% (announces 2024 budget)
  • TEX +2.4% (Director disclosed the purchase of 50000 shares at $50.69 - $51.20 worth nearly $2.6 mln)
  • NX +2.3% (CEO to become Chairman)
  • OXY +2.2% (Warren Buffett's Berkshire Hathaway bought another 10482162 shares worth approx. $589 mln (12/11-12/13 transaction dates))
  • CHSN +2.1% (expanding its new coffee brand in China)
  • RILY +1.9% (continued volatility)
  • TOL +1.8% (authorizes new repurchase plan)
  • MAT +1.7% (developing American Girl doll film)
  • SDGR +1.5% (Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event)
  • JMIA +1.2% (closing food delivery business)
  • DWAC +1.1% (received termination notices from PIPE Investors representing approximately $17500000 of the PIPE between November 2 2023 and November 20 2023)
  • AEO +1% (raises dividend)
  • EOG +1% (names new COO and CFO)
Analyst comments:
  • ALEC +10% (upgraded to Buy from Hold at Stifel)
  • IBP +2.7% (upgraded to Overweight from Neutral at JP Morgan)
  • IVZ +2.6% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
  • BLD +2.5% (upgraded to Overweight from Neutral at JP Morgan)
  • LYV +2.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
  • HST +2.2% (upgraded to Neutral from Underweight at JP Morgan)
  • BECN +2% (upgraded to Overweight from Neutral at JP Morgan)
  • CHH +1.2% (upgraded to Neutral from Underweight at JP Morgan)

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • ESPR +14.6%, CDXS +12.9%, SDRL +5.9%, CHSN +2.7%, NX +2.3%, HOOD +2.3%, TXG +2.3%, OXY +2.2%, JMIA +2%, RKLB +1.8%, CVE +1.8%, MAT +1.7%, CARR +1.6%, EOG +1.3%, DWAC +1.3%, TOL +1.2%, DDD +1%, ALK +1%, LNW +0.9%, CADE +0.8%, MDT +0.8%
  • Gapping down:
    • OCUL -17%, ASLE -10.5%, MDRX -10%, ADBE -5%, PBA -3.1%, ACAD -2.8%, RILY -2.3%, OR -1.4%, AEO -1.1%